{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:40:12Z","timestamp":1794627612128,"version":"4.9.1"},"reference-count":13,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":10618,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1983,7]]},"abstract":"<jats:p>The absorption and elimination of a single 500 mg dose of methyldopa has been studied after oral administration to 10 normal volunteers, 10 patients with coeliac disease, who were on a gluten\u2010free diet, and to five patients with Crohn's disease. In patients with Crohn's disease the percentage of the dose recovered in urine (24%) was about one\u2010half of normal (50%). This decreased absorption was associated with reduced plasma concentrations of both free and conjugated methyldopa and a decreased pharmacological response. In patients with coeliac disease the percentage of dose recovered in urine (43%) was similar to normals, indicating a normal absorption of the drug. However, the plasma concentrations of both free and conjugated methyldopa were significantly higher than normal, although there was no increase in drug\u2010related effects. These findings confirm the importance of using indices other than drug plasma concentrations in the assessment of bioavailability in disease states.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1983.tb02147.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T18:05:24Z","timestamp":1343325924000},"page":"77-83","source":"Crossref","is-referenced-by-count":12,"title":["The absorption and conjugation of methyldopa in patients with coeliac and Crohn's diseases during treatment."],"prefix":"10.1111","volume":"16","author":[{"given":"AG","family":"Renwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CL","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CF","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj1290001"},{"key":"e_1_2_1_3_1","first-page":"205","article-title":"The metabolism of methyldopa in hypertensive human subjects.","volume":"143","author":"BUHS R.P.","year":"1964","journal-title":"J. Pharmac. exp. Ther."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197619111"},{"key":"e_1_2_1_5_1","first-page":"264","article-title":"Pharmacokinetics of methyldopa in man.","volume":"198","author":"KWAN K.C.","year":"1976","journal-title":"J. Pharmac. exp. Ther."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197702010-00004"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/1.1.39"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.17.2.139"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197812282992604"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)92656-1"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00562310"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00645132"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01426.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.12.8.654"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1983.tb02147.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1983.tb02147.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T07:42:33Z","timestamp":1697787753000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1983.tb02147.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,7]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1983,7]]}},"alternative-id":["10.1111\/j.1365-2125.1983.tb02147.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb02147.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,7]]}}}